Interleukin Inhibitors Market Size, Share & Trend Analysis Report By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, IBD), By Type (IL-17, IL-23), And Segment Forecasts, 2019 - 2026

Published: Jul, 2019 | Pages: 103 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB's bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Further key findings from the report suggest:

• Psoriatic arthritis and IBD are projected to register fastest growth through to 2026

• IL-17 is likely to overtake IL-23 as the leading type by 2026

• IL-5 inhibitors for asthma to witness strong growth in the near future

• Asia Pacific is expected to exhibit the fastest regional growth

• Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration

 Table of Contents

Chapter 1. Methodology and Scope
                  1.1. Market Segmentation & Scope
                  1.2. Market Definition
                  1.3. Information Procurement
                      1.3.1. Purchased database
                      1.3.2. GVR's internal database
                      1.3.3. Secondary sources & third-party perspectives
                      1.3.4. Primary research
                  1.4. Information Analysis
                      1.4.1. Data analysis models
                  1.5. Market Formulation & Data Visualization
                  1.6. Data Validation & Publishing
Chapter 2. Executive Summary
                  2.1. Market Outlook 
                  2.2. Segment Outlook 
                  2.3. Competitive Insights
Chapter 3. Global Interleukin (IL) inhibitors Market Variables, Trends & Scope
                  3.1. Interleukin (IL) inhibitors Market Lineage outlook
                      3.1.1. Parent market outlook 
                  3.2. Penetration & Growth Prospect Mapping
                  3.3. Pipeline Analysis
                  3.4. Market Dynamics
                      3.4.1. Market driver analysis
                          3.4.1.1. Increasing prevalence of autoimmune diseases
                          3.4.1.2. Technological advancements 
                          3.4.1.3. Favorable government initiatives
                          3.4.1.4. Increasing consumer awareness 
                      3.4.2. Market restraint analysis
                          3.4.2.1. High cost of the treatment
                          3.4.2.2. Stringent regulatory approval
                  3.5. Interleukin (IL) inhibitors Market Analysis Tools
                      3.5.1. Industry analysis - Porter's
                          3.5.1.1. Supplier Power: Moderate due to long-term contracts with manufacturers
                          3.5.1.2. Buyer Power: Moderate due to low number of approved products
                          3.5.1.3. Substitution Threat: High due to emergence of biosimilar
                          3.5.1.4. Threat from New Entrant: High due to strong pipeline 
                          3.5.1.5. Competitive Rivalry: High due to increasing mergers & acquisitions by players
                      3.5.2. PESTEL Analysis
                          3.5.2.1. Political landscape
                          3.5.2.2. Environmental landscape
                          3.5.2.3. Social landscape
                          3.5.2.4. Technology landscape
                          3.5.2.5. Legal landscape
Chapter 4. Interleukin (IL) inhibitors Market: Application Estimates & Trend Analysis 
                  4.1. Definitions & Scope 
                  4.2. Application Market Share Analysis, 2018 & 2026
                  4.3. Application Dashboard 
                  4.4. Global Interleukin (IL) Inhibitors Market, by Application, 2014 to 2026
                  4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                      4.5.1. Psoriasis 
                          4.5.1.1. Psoriasis market, 2014 - 2026 (USD Million)
                      4.5.2. Psoriatic arthritis
                          4.5.2.1. Psoriatic arthritis market, 2014 - 2026 (USD Million)
                      4.5.3. Rheumatoid arthritis
                          4.5.3.1. Rheumatoid arthritis market, 2014 - 2026 (USD Million)
                      4.5.4. Asthma
                          4.5.4.1. Asthma market, 2014 - 2026 (USD Million)
                      4.5.5. Inflammatory Bowel Disease
                          4.5.5.1. Inflammatory bowel disease market, 2014 - 2026 (USD Million)
                      4.5.6. Others
                          4.5.6.1. Others market, 2014 - 2026 (USD Million)
Chapter 5. Interleukin (IL) inhibitors Market: Type Estimates & Trend Analysis 
                  5.1. Definitions & Scope 
                  5.2. Type Market Share Analysis, 2018 & 2026
                  5.3. Type Dashboard 
                  5.4. Global Interleukin (IL) inhibitors Market, by Type, 2014 to 2026
                  5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                      5.5.1. IL-17
                          5.5.1.1. IL-17 market, 2014 - 2026 (USD Million)
                      5.5.2. IL-23
                          5.5.2.1. IL-23 market, 2014 - 2026 (USD Million)
                      5.5.3. IL-1
                          5.5.3.1. IL-1 market, 2014 - 2026 (USD Million)
                      5.5.4. IL-5
                          5.5.4.1. IL-5 market, 2014 - 2026 (USD Million)
                      5.5.5. IL-6
                          5.5.5.1. IL-6 market, 2014 - 2026 (USD Million)
                      5.5.6. Others
                          5.5.6.1. Others market, 2014 - 2026 (USD Million)
Chapter 6. Interleukin (IL) Inhibitors Market: Regional Estimates & Trend Analysis, by Product, and Distribution Channel
                  6.1. Regional Market Snapshot 
                  6.2. Regional Market Share and Leading Players, 2018
                      6.2.1. North America
                      6.2.2. Europe
                      6.2.3. Asia Pacific
                      6.2.4. Latin America
                      6.2.5. Middle East & Africa
                  6.3. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
                      6.3.1. North America 
                      6.3.2. Europe
                      6.3.3. Asia Pacific
                      6.3.4. Latin America
                      6.3.5. Middle East & Africa
                  6.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                      6.4.1. North America 
                          6.4.1.1. North America interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.1.2. U.S.
                              6.4.1.2.1. U.S. interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.1.3. Canada
                              6.4.1.3.1. Canada interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                      6.4.2. Europe
                          6.4.2.1. Europe interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.2.2. U.K.
                              6.4.2.2.1. U.K. interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.2.3. Germany
                              6.4.2.3.1. Germany interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.2.4. Spain
                              6.4.2.4.1. Spain interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.2.5. France
                              6.4.2.5.1. France interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.2.6. Italy
                              6.4.2.6.1. Italy interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                      6.4.3. Asia Pacific
                          6.4.3.1. Asia Pacific interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.3.2. China
                              6.4.3.2.1. China interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.3.3. Japan
                              6.4.3.3.1. Japan interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.3.4. India
                              6.4.3.4.1. India interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.3.5. South Korea
                              6.4.3.5.1. South Korea interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.3.6. Australia
                              6.4.3.6.1. Australia interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                      6.4.4. Latin America
                          6.4.4.1. Latin America interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.4.2. Brazil
                              6.4.4.2.1. Brazil interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.4.3. Mexico
                              6.4.4.3.1. Mexico interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.4.4. Argentina
                              6.4.4.4.1. Argentina interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                      6.4.5. Middle East Africa
                          6.4.5.1. MEA interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.5.2. South Africa
                              6.4.5.2.1. South Africa interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.5.3. Saudi Arabia
                              6.4.5.3.1. Saudi Arabia interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
                          6.4.5.4. UAE
                              6.4.5.4.1. UAE interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
Chapter 7. Company Profiles
                  7.1. Recent Developments & Impact Analysis, by Key Market Participants
                  7.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
                  7.3. Public Companies
                      7.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                      7.3.2. Competitive dashboard analysis 
                      7.3.3. Market differentiators 
                  7.4. Private Companies 
                  7.5. Strategic Framework 
                  7.6. Company Profiles
                      7.6.1. Novartis AG
                          7.6.1.1. Company overview
                          7.6.1.2. Financial performance
                          7.6.1.3. Product benchmarking
                          7.6.1.4. Strategic initiatives
                      7.6.2. AbbVie Inc
                          7.6.2.1. Company overview
                          7.6.2.2. Financial performance
                          7.6.2.3. Product benchmarking
                          7.6.2.4. Strategic initiatives
                      7.6.3. Eli Lilly and Company
                          7.6.3.1. Company overview
                          7.6.3.2. Financial performance
                          7.6.3.3. Product benchmarking
                          7.6.3.4. Strategic initiatives
                      7.6.4. Regeneron Pharmaceuticals, Inc.
                          7.6.4.1. Company overview
                          7.6.4.2. Financial performance
                          7.6.4.3. Product benchmarking
                          7.6.4.4. Strategic initiatives
                      7.6.5. Johnson & Johnson Services, Inc
                          7.6.5.1. Company overview
                          7.6.5.2. Financial performance
                          7.6.5.3. Product benchmarking
                          7.6.5.4. Strategic initiatives
                      7.6.6. F. Hoffmann-La Roche Ltd
                          7.6.6.1. Company overview
                          7.6.6.2. Financial performance
                          7.6.6.3. Product benchmarking
                          7.6.6.4. Strategic initiatives
                      7.6.7. AstraZeneca
                          7.6.7.1. Company overview
                          7.6.7.2. Financial performance
                          7.6.7.3. Product benchmarking
                          7.6.7.4. Strategic initiatives
                      7.6.8. Bausch Health
                          7.6.8.1. Company overview
                          7.6.8.2. Financial performance
                          7.6.8.3. Product benchmarking
                          7.6.8.4. Strategic initiatives
                      7.6.9. GlaxoSmithKline plc
                          7.6.9.1. Company overview
                          7.6.9.2. Financial performance
                          7.6.9.3. Product benchmarking
                          7.6.9.4. Strategic initiatives
                      7.6.10. Teva Pharmaceuticals Industries, Ltd.
                          7.6.10.1. Company overview
                          7.6.10.2. Financial performance
                          7.6.10.3. Product benchmarking
                          7.6.10.4. Strategic initiatives

List of Tables

TABLE 1 List of abbreviation
TABLE 2 North America Interleukin (IL) inhibitors Market, by application, 2014 - 2026 (USD Million)
TABLE 3 North America Interleukin (IL) inhibitors market, by type, 2014 - 2026 (USD Million)
TABLE 4 U.S. Interleukin (IL) inhibitors market, by Application, 2014 - 2026 (USD Million)
TABLE 5 U.S. Interleukin (IL) inhibitors market, by type, 2014 - 2026 (USD Million)
TABLE 6 Canada Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 7 Canada Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 8 Europe Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 9 Europe Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 10 U.K. Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 11 U.K. Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 12 Germany Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 13 Germany Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 14 France Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 15 France Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 16 Italy Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 17 Italy Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 18 Spain Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 19 Spain Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 20 Asia Pacific Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 21 Asia Pacific Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 22 Japan Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 23 Japan Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 24 China Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 25 China Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 26 India Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 27 India Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 28 South Korea Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 29 South Korea Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 30 Australia Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 31 Australia Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 32 Latin America Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 33 Latin America Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 34 Brazil Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 35 Brazil Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 36 Mexico Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 37 Mexico Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 38 Argentina Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 39 Argentina Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 40 MEA Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 41 MEA Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 42 South Africa Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 43 South Africa Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 44 Saudi Arabia Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 45 Saudi Arabia Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)
TABLE 46 UAE Interleukin (IL) inhibitors Market, by Application, 2014 - 2026 (USD Million)
TABLE 47 UAE Interleukin (IL) inhibitors Market, by Type, 2014 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global interleukin (IL) inhibitors market - Key market driver analysis
FIG. 7 Global interleukin (IL) inhibitors market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Global interleukin (IL) inhibitors market - Porter's analysis
FIG. 10 Global interleukin (IL) inhibitors market - PESTEL analysis
FIG. 11 Global interleukin (IL) inhibitors market application outlook key takeaways
FIG. 12 Global interleukin (IL) inhibitors market: Application movement analysis
FIG. 13 Psoriasis market estimates, 2014 - 2026 (USD Million)
FIG. 14 Psoriatic arthritis market estimates, 2014 - 2026 (USD Million)
FIG. 15 Rheumatoid arthritis market estimates, 2014 - 2026 (USD Million)
FIG. 16 Asthma market estimates, 2014 - 2026 (USD Million)
FIG. 17 Inflammatory bowel disease market estimates, 2014 - 2026 (USD Million)
FIG. 18 Others market estimates, 2014 - 2026 (USD Million)
FIG. 19 Global interleukin (IL) inhibitors market type outlook key takeaways
FIG. 20 Global interleukin (IL) inhibitors market: Type movement analysis
FIG. 21 IL-17 market estimates, 2014 - 2026 (USD Million)
FIG. 22 IL-23 market estimates, 2014 - 2026 (USD Million)
FIG. 23 IL-1 market estimates, 2014 - 2026 (USD Million)
FIG. 24 IL-5 market estimates, 2014 - 2026 (USD Million)
FIG. 25 IL-6 market estimates, 2014 - 2026 (USD Million)
FIG. 26 Others market estimates, 2014 - 2026 (USD Million)
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 Global interleukin (IL) inhibitors market: Regional movement analysis
FIG. 29 North America interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 30 U.S. interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 31 Canada interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 32 Europe interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 33 U.K. interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 34 Germany interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 35 France interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 36 Spain interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 37 Italy interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 38 Asia Pacific interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 39 Japan interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 40 China interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 41 India interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 42 South Korea interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 43 Australia interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 44 Latin America interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 45 Brazil interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 46 Mexico interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 47 Argentina interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 48 MEA interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 49 South Africa interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 50 Saudi Arabia interleukin (IL) inhibitors market, 2014 - 2026 (USD Million)
FIG. 51 UAE market, 2014 - 2026 (USD Million)
FIG. 52 Strategy framework